Literature DB >> 22901196

Who are the breast cancer survivors in Malaysia?

Nor Idawaty Ibrahim1, M Dahlui, E N Aina, N Al-Sadat.   

Abstract

INTRODUCTION: Worldwide, breast cancer is the commonest cause of cancer death in women. However, the survival rate varies across regions at averages of 73%and 57% in the developed and developing countries, respectively.
OBJECTIVE: This study aimed to determine the survival rate of breast cancer among the women of Malaysia and characteristics of the survivors.
METHOD: A retrospective cohort study was conducted on secondary data obtained from the Breast Cancer Registry and medical records of breast cancer patients admitted to Hospital Kuala Lumpur from 2005 to 2009. Survival data were validated with National Birth and Death Registry. Statistical analysis applied logistic regression, the Cox proportional hazard model, the Kaplan-Meier method and log rank test.
RESULTS: A total of 868 women were diagnosed with breast cancer between January 2005 and December 2009, comprising 58%, 25% and 17% Malays, Chinese and Indians, respectively. The overall survival rate was 43.5% (CI 0.573-0.597), with Chinese, Indians and Malays having 5 year survival rates of 48.2% (CI 0.444-0.520), 47.2% (CI 0.432-0.512) and 39.7% (CI 0.373-0.421), respectively (p<0.05). The survival rate was lower as the stages increased, with the late stages were mostly seen among the Malays (46%), followed by Chinese (36%) and Indians (34%). Size of tumor>3.0cm; lymph node involvement, ERPR, and HER 2 status, delayed presentation and involvement of both breasts were among other factors that were associated with poor survival.
CONCLUSIONS: The overall survival rate of Malaysian women with breast cancer was lower than the western figures with Malays having the lowest because they presented at late stage, after a long duration of symptoms, had larger tumor size, and had more lymph nodes affected. There is an urgent need to conduct studies on why there is delay in diagnosis and treatment of breast cancer women in Malaysia.

Entities:  

Mesh:

Year:  2012        PMID: 22901196     DOI: 10.7314/apjcp.2012.13.5.2213

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  7 in total

1.  A meta-analysis of the association of glutathione S-transferase P1 gene polymorphism with the susceptibility of breast cancer.

Authors:  Jun-Jie Liu; Jin-Lu Liu; Xing Zhang; Lu Xie; Jian Zeng
Journal:  Mol Biol Rep       Date:  2013-01-19       Impact factor: 2.316

2.  Screening Uptake Differences Are Not Implicated in Poorer Breast Cancer Outcomes among Singaporean Malay Women.

Authors:  Wong Ru Xin; Li-Lian Kwok; Wong Fuh Yong
Journal:  J Breast Cancer       Date:  2017-06-26       Impact factor: 3.588

3.  A path analytic model of health beliefs on the behavioral adoption of breast self-examination.

Authors:  Soo-Foon Moey; Norfariha Che Mohamed; Bee-Chiu Lim
Journal:  AIMS Public Health       Date:  2020-12-21

4.  Net survival differences of breast cancer between stages at diagnosis and age groups in the east coast region of West Malaysia: a retrospective cohort study.

Authors:  Tengku Muhammad Hanis; Najib Majdi Yaacob; Suhaily Mohd Hairon; Sarimah Abdullah
Journal:  BMJ Open       Date:  2021-05-18       Impact factor: 2.692

Review 5.  A Scoping Review on the Status of Female Breast Cancer in Asia with a Special Focus on Nepal.

Authors:  Rojana Dhakal; Maria Noula; Zoe Roupa; Edna N Yamasaki
Journal:  Breast Cancer (Dove Med Press)       Date:  2022-08-26

6.  Survival Time and Prognostic Factors for Breast Cancer amongzzm321990Women in North-East Peninsular Malaysia

Authors:  Noorfariza Nordin; Najib Majdi Yaacob; Noor Hashimah Abdullah; Suhaily Mohd Hairon
Journal:  Asian Pac J Cancer Prev       Date:  2018-02-26

7.  Modelling excess mortality among breast cancer patients in the North East Region of Peninsular Malaysia, 2007-2011: a population-based study.

Authors:  Tengku Muhammad Hanis; Najib Majdi Yaacob; Suhaily Mohd Hairon; Sarimah Abdullah; Noorfariza Nordin; Noor Hashimah Abdullah; Mohd Faiz Md Ariffin
Journal:  BMC Public Health       Date:  2019-12-30       Impact factor: 3.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.